po-sa-KON-a-zole 
Spectrum:
Absorption: Well absorbed following oral administration; absorption is optimized by food; IV administration results in complete bioavailability.
Distribution: Extensive extravascular distribution and penetration into body tissues.
Protein Binding: >98%.
Metabolism/Excretion: Some metabolism via UDP glucuronidation; 66% eliminated unchanged in feces, 13% in urine (mostly as metabolites).
Half-life: 35 hr.
Contraindicated in:
Use Cautiously in:
CV: TORSADES DE POINTES, QT interval prolongation.
Endo: adrenal insufficiency.
F and E: hypokalemia, hypomagnesemia, hypocalcemia.
GI: HEPATOCELLULAR DAMAGE, PANCREATITIS, diarrhea, nausea, vomiting.
Neuro: headache.
Resp: cough.
Misc: HYPERSENSITIVITY REACTIONS, fever.
Drug-Drug:
Treatment of Invasive Aspergillosis
May switch between use of IV and delayed-release tablets (another loading dose is not needed when switching between formulations).
13 yr): Delayed-release tablets — 300 mg twice daily on Day 1, then 300 mg once daily starting on Day 2 for a total of 6–12 wk.13 yr): 300 mg twice daily on Day 1, then 300 mg once daily starting on Day 2 for a total of 6–12 wk.Prophylaxis of Invasive Aspergillus and Candida Infections
13 yr): Oral suspension — 200 mg 3 times daily. Duration of therapy is based on recovery from neutropenia or immunosuppression.2 yr and >40 kg): Delayed-release tablets — 300 mg twice daily on Day 1, then 300 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.2 yr and 36–40 kg): Delayed-release oral suspension — 240 mg twice daily on Day 1, then 240 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.2 yr and 26–<36 kg): Delayed-release oral suspension — 210 mg twice daily on Day 1, then 210 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.2 yr and 21–<26 kg): Delayed-release oral suspension — 180 mg twice daily on Day 1, then 180 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.2 yr and 17–<21 kg): Delayed-release oral suspension — 150 mg twice daily on Day 1, then 150 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.2 yr and 12–<17 kg): Delayed-release oral suspension — 120 mg twice daily on Day 1, then 120 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.2 yr and 10–<12 kg): Delayed-release oral suspension — 90 mg twice daily on Day 1, then 90 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.2 yr): 6 mg/kg (max = 300 mg) twice daily on Day 1, then 6 mg/kg (max = 300 mg) once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.Treatment of Oropharyngeal Candidiasis
13 yr): Oral suspension — 100 mg twice daily on Day 1, then 100 mg once daily for the next 13 days. For refractory oropharyngeal candidiasis, give 400 mg twice daily; duration of therapy is based on the severity of the patient’s underlying disease and clinical response.
3 mL; use BLUE syringe if dose >3 mL. Not all mixture in cup will be used. Use only the provided notched tip syringes To ensure delivery of the correct dose. Design of notched tip syringe prevents aggregation of the suspension during preparation and administration. Noxafil PowderMix is not recommended for patients weighing >40 kg; dose cannot be achieved with this formulation.IV Administration:
(Generic available)
(blood levels)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO (suspension) | unknown | 3–5 hr | 8 hr |
| PO-ER | unknown | 4–5 hr | 24 hr |
| IV | unknown | 2 hr | 24 hr |
NDC Code*